Skip to main content
PMC home page
Other Publishers logoLink to Other Publishers
. 2021 Jun 5;32(8):1068. doi: 10.1016/j.annonc.2021.05.797

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q'

[Annals of Oncology 30 (2019) 1821–1830]

KL Jhaveri 1,∗, XV Wang 2, V Makker 3, S-W Luoh 4, EP Mitchell 5, JA Zwiebel 6, E Sharon 7, RJ Gray 8, S Li 8, LM McShane 9, LV Rubinstein 10, D Patton 11, PM Williams 12, SR Hamilton 13, BA Conley 14, CL Arteaga 15, LN Harris 14, PJ O’Dwyer 16, AP Chen 17, KT Flaherty 18
PMCID: PMC8929237  PMID: 34099371

The authors regret that Dr Arteaga’s disclosures were not complete in the original publication. Dr Arteaga’s full disclosure should read as follows:

CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare.

The authors would like to apologise for any inconvenience caused.

RESOURCES